Tyra Biosciences, Inc. (TYRA) Stock Score, Valuation & Financial Research

Tyra Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TYRA

Tyra Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 20.24. These figures are a research snapshot, not a buy or sell recommendation.

What Tyra Biosciences, Inc. does

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Tyra Biosciences is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on research and development of precision medicines, funded primarily through capital raises and potential future licensing or collaboration agreements for its proprietary drug candidates.

Products and services

  • The company is developing a pipeline of small molecule inhibitors, including its lead candidate TYRA-300, which targets FGFR3 for the treatment of oncology indications and skeletal dysplasias.

Brands and product families

  • TYRA — Corporate brand and trademarked name for the company's drug discovery platform and programs. Source

Customer types

Patients with FGFR-related cancers and skeletal dysplasias.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for clinical trial management, data collection, and the manufacturing of drug substance and drug product for clinical use; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing targeted therapies for oncology and genetically defined conditions, including those targeting FGFR biology. Source

Business strengths to evaluate

  • Proprietary SNÅP platform for small molecule drug discovery Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of lead product candidate TYRA-300 Source
  • Risks associated with clinical trial development and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TYRA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 20.24
Market capitalization:
1.21B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -148.57M
Free cash flow:
USD -95.28M
Cash:
USD 73.84M
Total debt:
USD 5.58M
EPS:
USD -2.40

What stands out

  • Free cash flow is USD -95.28M, negative for the stored period.
  • The balance sheet shows USD 73.84M of cash versus USD 5.58M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 68.25M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TYRA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TYRA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TYRA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TYRA to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of TYRA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TYRA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.